| Name | CH7057288 |
|---|---|
| Synonyms |
4-Pyridinecboxamide, 2-[2-[6,11-dihydro-6,6-dimethyl-8-[(methylsulfonyl)amino]-11-oxobenzo[b]naphtho[2,3-d]furan-3-yl]ethynyl]-N-(1,1-dimethylethyl)-6-methyl
CH7057288, 10 mM in DMSO Inhibitor,Trk Rector,CH7057288,inhibit,Tropomyosin related kinase rector,CH 7057288,CH-7057288 |
| Description | CH7057288 is a potent and selective TRK inhibitor. |
|---|---|
| Related Catalog | |
| Target |
TRK |
| In Vitro | CH7057288 induces regression of intracranial tumors and greatly improves event-free survival in an intracranial implantation model mimicking brain metastasis. CH7057288 can be a promising therapeutic agent for TRK fusion-positive cancer. TRK receptor tyrosine kinases are expressed as fusion proteins encoded by various fusion genes across a wide variety of cancer types, including lung and colorectal cancer[1]. |
| References |
| Molecular Formula | C32H31N3O5S |
|---|---|
| Molecular Weight | 569.67 |
| Storage condition | 2-8℃ |